Skip to content

INVESTOR CENTRE

Company Overview

Bionomics (ASX:BNO, OTCQB:BNOEF) is a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead product candidate, BNC210, an oral proprietary selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (“SAD”) and chronic treatment of Post-Traumatic Stress Disorder (“PTSD”).

Bionomics has a strategic partnership with Merck & Co., Inc with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.

Bionomics is currently based in Australia and listed on the Australian Securities Exchange (ASX) under the code BNO (BNO.AX) and trades on the US OTCQX market under the ticker BNOEF.


ANNOUNCEMENTS


asx-logo

View ASX Announcements

PRESENTATIONS


Latest Presentations

SHARE PRICE INFORMATION

Share Price Information

CONTACT US

Share Ownership

 

For any queries relating to Bionomics shares (e.g. updating contact or ownership details, dividend payments etc) please contact:

Computershare Investor Services Pty Ltd
Level 5, 115 Grenfell Street
Adelaide, SA 5000
Telephone: (08) 8236 2300
Facsimile: (08) 8236 2305